Checkpoint Therapeutics Inc (CKPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) has a cash flow conversion efficiency ratio of -0.717x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.69 Million) by net assets ($16.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Checkpoint Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Checkpoint Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Checkpoint Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Checkpoint Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Checkpoint Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Van de Velde NV
BR:VAN
|
0.127x |
|
Andes Technology Corp
TW:6533
|
-0.006x |
|
Kolte - Patil Developers Limited
NSE:KOLTEPATIL
|
0.134x |
|
Mesabi Trust
NYSE:MSB
|
0.514x |
|
Newtek Business Services Corp
NASDAQ:NEWT
|
-0.421x |
|
Zhangjiagang Haiguo New Energy Equipment Manufacturing Co. Ltd.
SHE:301063
|
N/A |
|
Jiangxi Hengda Hi-Tech Co Ltd
SHE:002591
|
-0.032x |
|
2CRSI S.A.
PA:AL2SI
|
0.123x |
Annual Cash Flow Conversion Efficiency for Checkpoint Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Checkpoint Therapeutics Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Checkpoint Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-12.62 Million | $-31.10 Million | 2.463x | -32.46% |
| 2023-12-31 | $-13.05 Million | $-47.59 Million | 3.648x | +23.48% |
| 2022-12-31 | $-19.48 Million | $-57.55 Million | 2.954x | +434.04% |
| 2021-12-31 | $29.75 Million | $-26.31 Million | -0.884x | -89.04% |
| 2020-12-31 | $35.38 Million | $-16.55 Million | -0.468x | +58.75% |
| 2019-12-31 | $18.85 Million | $-21.37 Million | -1.134x | +48.12% |
| 2018-12-31 | $11.81 Million | $-25.80 Million | -2.186x | -112.64% |
| 2017-12-31 | $15.04 Million | $-15.46 Million | -1.028x | -233.74% |
| 2016-12-31 | $32.30 Million | $-9.95 Million | -0.308x | -1189.72% |
| 2015-12-31 | $46.40 Million | $-1.11 Million | -0.024x | -- |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more